- Home
- GBDC vs DNLI Comparison
GBDC vs DNLI Comparison
Compare GBDC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBDC
- DNLI
- Stock Information
- Founded
- GBDC 2009
- DNLI 2013
- Country
- GBDC United States
- DNLI United States
- Employees
- GBDC N/A
- DNLI N/A
- Industry
- GBDC Finance: Consumer Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBDC Finance
- DNLI Health Care
- Exchange
- GBDC Nasdaq
- DNLI Nasdaq
- Market Cap
- GBDC 4.0B
- DNLI 3.3B
- IPO Year
- GBDC 2010
- DNLI 2017
- Fundamental
- Price
- GBDC $15.40
- DNLI $21.93
- Analyst Decision
- GBDC Buy
- DNLI Strong Buy
- Analyst Count
- GBDC 6
- DNLI 13
- Target Price
- GBDC $16.25
- DNLI $38.91
- AVG Volume (30 Days)
- GBDC 1.2M
- DNLI 1.1M
- Earning Date
- GBDC 02-04-2025
- DNLI 02-25-2025
- Dividend Yield
- GBDC 10.13%
- DNLI N/A
- EPS Growth
- GBDC N/A
- DNLI N/A
- EPS
- GBDC 1.36
- DNLI N/A
- Revenue
- GBDC $724,677,000.00
- DNLI N/A
- Revenue This Year
- GBDC $23.90
- DNLI N/A
- Revenue Next Year
- GBDC N/A
- DNLI $651.24
- P/E Ratio
- GBDC $11.32
- DNLI N/A
- Revenue Growth
- GBDC 20.16
- DNLI 204.74
- 52 Week Low
- GBDC $14.05
- DNLI $14.56
- 52 Week High
- GBDC $17.72
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- GBDC 58.22
- DNLI 51.28
- Support Level
- GBDC $15.18
- DNLI $18.52
- Resistance Level
- GBDC $15.41
- DNLI $22.37
- Average True Range (ATR)
- GBDC 0.17
- DNLI 1.31
- MACD
- GBDC 0.04
- DNLI 0.31
- Stochastic Oscillator
- GBDC 96.77
- DNLI 88.57
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.